comparemela.com
Home
Live Updates
89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafe
89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafe
89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis at EASL International Liver Congress
89bio, Inc. announced that data from the 48-week extension phase of the Phase 2b ENLIVEN trial evaluating pegozafermin in patients with metabolic dysfunction-associated steatohepatitis with fibrosis...
Related Keywords
Italy ,
Milan ,
Lombardia ,
,
Drug Administration ,
European Association ,
Breakthrough Therapy ,
Priority Medicines ,
European Medicines Agenda ,